ALK and non-small cell lung carcinoma: In 2007, the EML4–ALK rearrangement was first identified when 7% of a small cohort of Japanese patients with NSCLC was found to harbor the EML4 rearrangement, which fused to ALK, leading to the creation of the oncogene EML4–ALK (3).